Clinical Outcomes of Infective Endocarditis in Injection Drug Users.

J Am Coll Cardiol

Cardiovascular Outcomes Research Laboratories, Division of Cardiac Surgery, David Geffen School of Medicine, University of California, Los Angeles, California. Electronic address:

Published: February 2019

Background: Rising rates of hospitalization for infective endocarditis (IE) have been increasingly tied to rising injection drug use (IDU) associated with the opioid epidemic.

Objectives: This study analyzed recent trends in IDU-IE hospitalization and characterized outcomes and readmissions for IDU-IE patients.

Methods: The authors evaluated the National Readmissions Database (NRD) for IE cases between January 2010 and September 2015. Patients were stratified by IDU status and surgical versus medical management. Primary outcome was 30-day readmission and cause, with secondary outcomes including mortality, length of stay (LOS), adjusted costs, and 180-day readmission. The Kruskal-Wallis and chi-square tests were used to analyze baseline differences by IDU status. Multivariable regressions were used to analyze mortality, readmissions, LOS, and adjusted costs.

Results: The survey-weighted sample contained 96,344 (77.8%) non-IDU-IE and 27,432 (22.2%) IDU-IE cases. IDU-IE increased from 15.3% to 29.1% of IE cases between 2010 and 2015 (p < 0.001). At index hospitalization, IDU-IE was associated with reduced mortality (6.8% vs. 9.6%; p < 0.001) but not 30-day readmission (23.8% vs. 22.9%; p = 0.077) relative to non-IDU-IE. Medically managed IDU-IE patients had higher LOS (β = 1.36 days; 95% confidence interval [CI]: 0.71 to 2.01), reduced costs (β = -$4,427; 95% CI: -$7,093 to -$1,761), and increased readmission for endocarditis (18.1% vs. 5.6%; p < 0.001), septicemia (14.0% vs. 7.3%; p < 0.001), and drug abuse (4.3% vs. 0.7%; p < 0.001) compared with medically managed non-IDU-IE. Surgically managed IDU-IE patients had increased LOS (β = 4.26 days; 95% CI: 2.73 to 5.80) and readmission for septicemia (15.6% vs. 5.2%; p < 0.001) and drug abuse (7.3% vs. 0.9%; p < 0.001) compared with non-IDU-IE.

Conclusions: The incidence of IDU-IE continues to rise nationally. Given the increased readmission for endocarditis, septicemia, and drug abuse, IDU-IE presents a serious challenge to current management of IE.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.10.082DOI Listing

Publication Analysis

Top Keywords

p < 0001
24
infective endocarditis
8
injection drug
8
idu status
8
30-day readmission
8
los adjusted
8
medically managed
8
managed idu-ie
8
idu-ie patients
8
0001 drug
8

Similar Publications

Gut microbial-derived phenylacetylglutamine accelerates host cellular senescence.

Nat Aging

January 2025

National Clinical Research Center for Aging and Medicine, Huashan Hospital and MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Gut microbiota plays a crucial role in the host health in the aging process. However, the mechanisms for how gut microbiota triggers cellular senescence and the consequent impact on human aging remain enigmatic. Here we show that phenylacetylglutamine (PAGln), a metabolite linked to gut microbiota, drives host cellular senescence.

View Article and Find Full Text PDF

The article is devoted to the creation of enzymatic nanoreactors based on polystyrene-block-poly(acrylic acid) (PS-b-PAA) copolymers containing bioscavengers capable of neutralizing toxic esters both in the body and in the environment. Block copolymers of different amphiphilicity, hydrophilicity and molecular weights were synthesized and characterized using gel permeation chromatography, NMR and UV spectroscopy. Polymeric nanocontainers in the absence and presence of human butyrylcholinesterase were made by film hydration and characterized by dynamic light scattering and microscopy methods.

View Article and Find Full Text PDF

Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.

View Article and Find Full Text PDF

Estimating the time-varying emission rate of peracetic acid.

Ann Work Expo Health

January 2025

Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 N Wolfe St, Baltimore, MD 21205, United States.

The use of peracetic acid (PAA) as a general disinfectant has seen increasing usage in recent years, and although it is a strong irritant, exposure monitoring for PAA may often be difficult due to relatively high costs and the potential for interferences by other co-occurring chemicals such as hydrogen peroxide. These issues with exposure monitoring make modeling a potentially useful tool in exposure assessment of PAA if model parameters can be accurately determined. This study estimates the time-varying mass emission rate of PAA for use in exposure modeling by using the small spill model and examines the effect of various environmental conditions on the PAA evaporation rate, including surface roughness/substrate, general ventilation rate, and local wind speed.

View Article and Find Full Text PDF

This work aims to deal with the challenges associated with designing complementary bifunctional electrocatalysts and a separator/membrane that enables rechargeable zinc-air batteries (RZABs) with nearly solid-state operability. This solid-state RZAB was accomplished by integrating a bifunctional electrocatalyst based on Ru-RuO interface nanoparticles supported on nitrogen-doped (N-doped) graphene (Ru-RuO/NGr) and a dual-doped poly(acrylic acid) hydrogel (d-PAA) electrolyte soaked in KOH with sodium stannate additive. The catalyst shows enhanced activity and stability toward the two oxygen reactions, i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!